New pill could cure parasitic skin disease in months

NCT ID NCT06997159

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two doses of an experimental oral drug, LXE408, against a standard treatment (miltefosine) for localized cutaneous leishmaniasis, a parasitic skin disease. About 250 adults in the Americas will take the medicine for several weeks. The main goal is to see if the sores heal completely by day 90 and stay healed through day 180 without relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED CUTANEOUS LEISHMANIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous leishmaniasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Federal University of Maranhão

    São Luís, Maranhão, Brazil

    Contact

    Contact

  • Foundation of Tropical Medicine Dr. Heitor Vieira Dourado

    Manaus, Amazonas, Brazil

    Contact

    Contact

  • Instituto Conmemorativo Gorgas de Estudios de la Salud

    Panama City, Panama

    Contact

    Contact

  • Julio Muller University Hospital/ Federal University of Mato Grosso

    Cuiabá, Mato Grosso, Brazil

    Contact

    Contact

  • René Rachou Institute /Oswaldo Cruz Foundation- FIOCRUZ MINAS

    Belo Horizonte, Minas Gerais, Brazil

    Contact

    Contact